INDV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.30% compare to its pairs and should correct upwards.

Stats
Today's Volume	184 496
Average Volume	99 027
Market Cap	2.16B
Next earnings date	( $0.460 ) 2024-07-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	403.00 (Sector) 42.63 (Industry) 30.78
ATR14	$0.0260 (0.16%)

AERI 0.00%

ALVO 1.33%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 0.00%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO 0.06%

INDV -1.59%

JUPWW -20.00%

LFCR -0.19%

LNDC -3.52%

LSDI -23.29%

PRFX -3.65%

PROCW 10.09%

QLI 6.82%

SBFMW 0.00%

SHOT 9.43%

SHPH 4.28%

Correlation (AI algo v.1.1b): Undervalued: 0.30% $16.22 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.17 (neutral)

Short: 0.91 (very strong)

Signal:(69.664) Expect same movement, but be aware

Indivior PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Indivior PLC Correlation - Currency/Commodity

-0.57
( weak negative )

0.14
( neutral )

0.00
( neutral )

-0.63
( weak negative )

0.00
( neutral )

0.49
( neutral )

Financial Reports:

No articles found.

Indivior PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.